A multi-task deep learning model for EGFR genotyping prediction and GTV segmentation of brain metastasis

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 71 209-249

[2] Ferlay J(2022)Lung adenocarcinoma tumor origin: a guide for personalized medicine Cancers 14 1759-6

[3] Siegel RL(2013)Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases Curr Oncol 20 300-3234

[4] Laversanne M(2021)Treatment of brain metastases of non-small cell lung carcinoma Int J Mol Sci 22 593-67

[5] Soerjomataram I(2023)Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor Eur J Pharmacol 945 3230-47

[6] Jemal A(2021)Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer J Thorac Dis 13 59-201

[7] Bray F(2018)Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors Cancer Treat Rev 71 38-279

[8] Seguin L(2017)Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going Crit Rev Oncol Hematol 117 189-1307

[9] Durandy M(2021)Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs Clin Cancer Res 27 268-14270

[10] Feral CC(2019)EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases Transl Lung Cancer Res 8 1298-84

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 71 209-249

[2] Ferlay J(2022)Lung adenocarcinoma tumor origin: a guide for personalized medicine Cancers 14 1759-6

[3] Siegel RL(2013)Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases Curr Oncol 20 300-3234

[4] Laversanne M(2021)Treatment of brain metastases of non-small cell lung carcinoma Int J Mol Sci 22 593-67

[5] Soerjomataram I(2023)Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor Eur J Pharmacol 945 3230-47

[6] Jemal A(2021)Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer J Thorac Dis 13 59-201

[7] Bray F(2018)Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors Cancer Treat Rev 71 38-279

[8] Seguin L(2017)Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going Crit Rev Oncol Hematol 117 189-1307

[9] Durandy M(2021)Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs Clin Cancer Res 27 268-14270

[10] Feral CC(2019)EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases Transl Lung Cancer Res 8 1298-84